Preclinical studies have shown that iadademstat can synergize with immune check-point inhibitors (ICI), providing a promising avenue to treat so-called immunological cold solid tumors.

Nov 17, 2025 · Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage …

Further trials can potentially explore its utilization to treat not only solid tumors but also small-cell lung cancer and certain types of lymphomas, as these cancers exhibit LSD1-dependent activity. Early lab …

Nov 5, 2021 · Iadademstat (iada) selectively inhibits LSD1 and has shown efficacy in preclinical models, including promoting differentiation in AML. Iada has been administered so far to +100 oncology …

Dec 16, 2024 · Despite the solid tumor focus, both solid and hematologic cancers can harbor identical driver molecular abnormalities and respond to cognate therapies.

1 day ago · Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), neuroendocrine …

Iadademstat is an orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity.

Mar 18, 2020 · Here, we tested the ability of the clinically proven inhibitor of the lysine-specific demethylase 1 (LSD1/KDM1A) iadademstat (ORY-100) to target SOX2-driven CSC in breast cancer.

Nov 13, 2019 · Acute Myeloid Leukemia (AML) is an elderly disease with a rising incidence in the past decades. Probability to achieve complete remission and survival rates decrease with age with …

Nov 15, 2022 · One such investigational strategy is iadademstat (iada), an oral, potent and selective inhibitor of the Lysine-Specific Demethylase 1 (LSD1/KDMA1) enzyme.